01 / Research notes
The fragment is a different research question
Search results often group TB-500 with thymosin beta-4 and then carry findings from the full protein over to the fragment. They are not interchangeable. A recent review of BPC-157 and TB-500 research found inadequate clinical validation of musculoskeletal benefits and no established human dosing for these uses.
Anecdotes about injection-site symptoms, headache, or fatigue cannot tell us how often such events happen or whether the peptide caused them. Small or absent human trials also make rare and long-term harms hard to detect.
02 / Research notes
Product quality and immune response
FDA has identified possible immunogenicity and impurity concerns for compounded TB-500. The source of the ingredient, its identity, and lot-specific testing matter. A research-use product sold online is not evidence that a formulation meets the HHS policy conditions or is appropriate for a patient.
Report new or worsening symptoms to the treating clinician. Severe reactions, including breathing difficulty or facial swelling, need urgent medical attention.
03 / Research notes
A clinical path for a slow-healing injury
Delayed healing can have treatable causes, including infection, impaired circulation, or an underlying condition. A clinician can examine the problem, review current treatments, and discuss evidence-based care before any investigational option.
The HHS interim policy addresses certain single-ingredient TB-500 acetate preparations under specific 503A conditions. It does not approve TB-500 or a BPC-157/TB-500 combination product.
Common questions
Are TB-500 side effects well studied in humans?
No. Available human evidence is too limited for a reliable adverse-event rate or long-term safety conclusion.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a fragment; data on the full protein cannot be assumed to apply to it.
Is there an approved TB-500 dosage?
No FDA-approved TB-500 dosing regimen has been established.
Sources and important information
Compounded drugs are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. HHS's interim policy is conditional and may change. Treatment through Jonathan Larson MDPC requires clinical evaluation; a licensed provider decides whether any prescription is medically necessary and appropriate. This guide is informational, not medical advice.